Daniela Couto
Directeur/Membre du Conseil chez Complement Therapeutics Ltd.
Postes actifs de Daniela Couto
Sociétés | Poste | Début | Fin |
---|---|---|---|
Biogeneration Management BV
Biogeneration Management BV Investment ManagersFinance Biogeneration Management is a venture capital firm, a subsidiary of BioGeneration Holding BV and was founded in 2006. Biogeneration management is headquartered in Naarden. | Private Equity Investor | 01/09/2015 | - |
Analyste en capital-investissement | 01/01/2005 | 01/09/2015 | |
Citryll BV
Citryll BV Miscellaneous Commercial ServicesCommercial Services Citryll BV is a private pharmaceutical company located in Oss, the Netherlands, at the Pivot Park. Citryll is dedicated to developing and commercializing therapeutics that target netosis and NETs, with a focus on immune-mediated inflammatory diseases. The Dutch company's lead antibody, Cit-013, has a unique dual mode of action and proprietary NET biomarker assays, making it a promising drug for rheumatoid arthritis and hidradenitis suppurativa. The initial clinical trials with Cit-013 are expected to provide the foundation for a new treatment paradigm for immune-mediated inflammatory diseases. The company was founded in 2015 by Helmuth van Es, Renato Chirivi, and the late Jos Raats of ModiQuest. | Directeur/Membre du Conseil | - | - |
Complement Therapeutics Ltd.
Complement Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Complement Therapeutics Ltd. develops medicines that target the complement system. The British company was founded by Richard Unwin, Simon J. Clark, and Paul Bishop. The CEO is Rafiq Hasan. | Directeur/Membre du Conseil | - | - |
Historique de carrière de Daniela Couto
Anciens postes connus de Daniela Couto
Sociétés | Poste | Début | Fin |
---|---|---|---|
Staten Biotechnology BV
Staten Biotechnology BV BiotechnologyHealth Technology Staten Biotechnology BV develops drugs for the treatment of dyslipidemia. The company was founded by Paul da Silva Jardine, Daniel Rader and Alan Tall in 2014 and is headquartered in Nijmegen, the Netherlands. | Directeur Général | - | - |
Cell2B - Advanced Therapeutics SA
Cell2B - Advanced Therapeutics SA BiotechnologyHealth Technology Cell2B - Advanced Therapeutics SA engages in the development of stem cell therapies for immune and inflammatory diseases. Its pipeline consists of cord blood unit expansion and anti-rejection medications. The company was founded by Daniela Couto, David Braga Malta, Francisco dos Santos, and Pedro Andrade in 2011 and is headquartered in Cantanhede, Portugal. | Directeur/Membre du Conseil | 01/01/2011 | - |
Directeur Général | 01/01/2011 | - | |
Fondateur | 01/01/2011 | - |
Formation de Daniela Couto
Universidade Técnica de Lisboa | Doctorate Degree |
University of Minho | Graduate Degree |
Statistiques
Internationale
Portugal | 4 |
Pays-Bas | 4 |
Royaume-Uni | 2 |
Opérationnelle
Director/Board Member | 3 |
Chief Executive Officer | 2 |
Founder | 1 |
Sectorielle
Health Technology | 4 |
Consumer Services | 3 |
Finance | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Entreprise privées | 5 |
---|---|
Cell2B - Advanced Therapeutics SA
Cell2B - Advanced Therapeutics SA BiotechnologyHealth Technology Cell2B - Advanced Therapeutics SA engages in the development of stem cell therapies for immune and inflammatory diseases. Its pipeline consists of cord blood unit expansion and anti-rejection medications. The company was founded by Daniela Couto, David Braga Malta, Francisco dos Santos, and Pedro Andrade in 2011 and is headquartered in Cantanhede, Portugal. | Health Technology |
Biogeneration Management BV
Biogeneration Management BV Investment ManagersFinance Biogeneration Management is a venture capital firm, a subsidiary of BioGeneration Holding BV and was founded in 2006. Biogeneration management is headquartered in Naarden. | Finance |
Staten Biotechnology BV
Staten Biotechnology BV BiotechnologyHealth Technology Staten Biotechnology BV develops drugs for the treatment of dyslipidemia. The company was founded by Paul da Silva Jardine, Daniel Rader and Alan Tall in 2014 and is headquartered in Nijmegen, the Netherlands. | Health Technology |
Citryll BV
Citryll BV Miscellaneous Commercial ServicesCommercial Services Citryll BV is a private pharmaceutical company located in Oss, the Netherlands, at the Pivot Park. Citryll is dedicated to developing and commercializing therapeutics that target netosis and NETs, with a focus on immune-mediated inflammatory diseases. The Dutch company's lead antibody, Cit-013, has a unique dual mode of action and proprietary NET biomarker assays, making it a promising drug for rheumatoid arthritis and hidradenitis suppurativa. The initial clinical trials with Cit-013 are expected to provide the foundation for a new treatment paradigm for immune-mediated inflammatory diseases. The company was founded in 2015 by Helmuth van Es, Renato Chirivi, and the late Jos Raats of ModiQuest. | Commercial Services |
Complement Therapeutics Ltd.
Complement Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Complement Therapeutics Ltd. develops medicines that target the complement system. The British company was founded by Richard Unwin, Simon J. Clark, and Paul Bishop. The CEO is Rafiq Hasan. | Health Technology |
- Bourse
- Insiders
- Daniela Couto
- Expérience